BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
New science points to 4 distinct types of autism - 2Ocean side Objections: Staggering Waterfront Breaks
- 3Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- 4Famous Network programs in Europe and America
- 5Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Well known SUVs With Low Energy Utilization In 2024 vote
- The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- Vote in favor of your Number one Kind of Gems
- What did the gov’t approve for Israel’s 2026 state budget?
- The Best 15 Applications for Efficiency and Association
- Misjudged Objections For Solo Voyagers
- Russia downs 16 drones heading for Moscow, mayor says
- Manual for Individual accounting Rudiments for Fledglings
